The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
Ebola Virus and Plasma Protein Therapies +
The recent outbreak of Ebola virus has caused great concern among many people. We read stories about isolation, experimental therapies and many deaths. It is understandable that this raises questions for persons who are more vulnerable to infections such as persons with immunedeficencies. We have seen questions and concerns expressed by various persons and would like to provide information about the safety of immune globulins.Read More
International Plasma Awareness Week to Celebrate Donors and Spotlight Rare Diseases +
Annapolis, MD--The second annual International Plasma Awareness Week (IPAW) will be celebrated October 12-18. A joint initiative of the Plasma Protein Therapeutics Association (PPTA) and its member companies, IPAW is designed to:Read More
PPTA 2014 Business Forum +
Registration now open!
The 2014 PPTA Business Forum will be held October 26th in Philadelphia, Pennsylvania.
[This event is for PPTA Members Only]Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly.
Read the current issue.